Nexavar Dosing in Renal Cancer Patients in Real-life Setting

Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01557127

Acronym

NEXST

Enrollment

205

Registered

2012-03-19

Start date

2011-11-01

Completion date

2016-03-31

Last updated

2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Renal Cell

Keywords

Renal cell carcinoma,, Sorafenib, Dosing

Brief summary

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in real-life setting vs. the prescribed dose.

Interventions

DRUGSorafenib (Nexavar, BAY43-9006)

Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>/= 18 years * Diagnosis of renal cell carcinoma * Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2 * Patients in whom the oncologist has decide to start therapy with sorafenib.

Exclusion criteria

* Synonymous with contraindications to Nexavar.

Design outcomes

Primary

Measure	Time frame
Percentage of patients in whom the actual dose of sorafenib equaled the planned dose	12 months

Secondary

Measure	Time frame
Overall tolerability of treatment as measured by rate of adverse events	12 months

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026